Evidence map›Paper›PMID 31302707›Full record

Trial reportDiabetologia2019

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.

Megumi Oshima, Min Jun, Toshiaki Ohkuma, Tadashi Toyama, Takashi Wada, Mark E Cooper, Samy Hadjadj, Pavel Hamet, Stephen Harrap, Giuseppe Mancia and 6 more

2 registry-linked trialsOpen access · hybridAbstract readObservational StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00145925 phase3completednot on this map

ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation

TypeinterventionalSponsorThe George InstituteRan2001 to 2008Enrolled11,140ConditionsDiabetes Mellitus, Type 2ArmsPerindopril-indapamide, Gliclazide MR-based glucose lowering
NCT00949286 completednot on this map

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

TypeobservationalSponsorThe George InstituteRan2010 to 2014Enrolled8,494ConditionsDiabetes Mellitus, Type 2
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 7 countries.

Megumi OshimaThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia.ORCID http://orcid.org/0000-0002-4108-5229
Min JunThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia.
Toshiaki OhkumaThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia.
Tadashi ToyamaThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia.
Takashi WadaDepartment of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.
Mark E CooperDiabetes Domain, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Samy HadjadjDepartment of Endocrinology, Institut du Thorax, Inserm, CNRS, CHU Nantes, Nantes, France.
Pavel HametCentre de Recherche, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Stephen HarrapDepartment of Physiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
Giuseppe ManciaDepartment of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Michel MarreDepartment of Endocrinology, Hôpital Bichat-Claude Bernard, Université Paris, Paris, France.
Bryan WilliamsInstitute of Cardiovascular Science, University College London and National Institute of Health Research UCL Hospitals Biomedical Research Centre, London, UK.
John ChalmersThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia.
Mark WoodwardThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia. mark.woodward@georgeinstitute.ox.ac.uk.
Vlado PerkovicThe George Institute for Global Health, University of New South Wales, Sydney, Level 5, 1 King St, Newtown, NSW, 2042, Australia. VPerkovic@georgeinstitute.org.au.
ADVANCE Collaborative Group
Kanazawa University · JPCentre National de la Recherche Scientifique · FRJohns Hopkins University · USThe Royal Melbourne Hospital · AUUniversité Claude Bernard Lyon 1 · FRUNSW Sydney · AUThe George Institute for Global Health · AU

Funding

Medical Research Council MC_PC_13090
6 · The paper itself

Abstract

aims/hypothesisSome studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear.

methodsWe used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study's primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation.

resultsA total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min CONCLUSIONS/

interpretationOur study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. TRIAL REGISTRY NUMBER: ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286.

Indexed as

Glomerular Filtration RateMortalityAgedBiomarkersChronic DiseaseCreatinineDiabetes Mellitus, Type 2FemaleHumansKidney Failure, ChronicLinear ModelsMaleMiddle AgedProportional Hazards ModelsRenal Insufficiency, ChronicRiskBiomarkersCreatinineCardiovascular diseaseeGFR slopeEnd-stage kidney diseaseMortalitySurrogate endpointType 2 diabetes

Identifiers

PMID31302707
PMCPMC6805825
OpenAlexW2960904779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.